Understanding the Long-Term Effects of SARS-CoV-2 Infection

Research Findings on MIS-C and Kawasaki Disease

Scientists are making significant strides in understanding the enduring consequences of SARS-CoV-2 infection. A team of researchers utilizing artificial intelligence has discovered that multisystem inflammatory syndrome in children (MIS-C), a post-COVID condition, elicits a similar immune response to both Kawasaki Disease (KD) and SARS-CoV-2 infection. However, MIS-C is noted for having a more intense immune response compared to KD. The researchers aim for these insights to assist clinicians in the treatment of both conditions.

What is MIS-C?

Definition and Symptoms

Multisystem inflammatory syndrome, or MIS-C, is a rare condition that emerges in children and adolescents following exposure to SARS-CoV-2, the virus responsible for COVID-19. The initial cases were reported in the United Kingdom in April 2020, coinciding with the onset of the COVID-19 pandemic. Symptoms of MIS-C can include fever, rash, gastrointestinal issues, and elevated levels of SARS-CoV-2 antibodies. Additionally, affected children may experience dilation of the coronary arteries, which supply blood to the heart, as well as myocardial dysfunction, which refers to irregularities in heart muscle function. Symptoms typically manifest within 4 to 6 weeks after SARS-CoV-2 exposure.

Similarities with Kawasaki Disease

Kawasaki Disease (KD) is another inflammatory condition primarily affecting younger children and is also considered rare. Current research indicates that KD may be triggered by an immune response to various infections, including those caused by viruses, bacteria, and fungi. While both MIS-C and KD exhibit overlapping cardiac symptoms, KD has the potential to cause coronary artery aneurysms and heart attacks. The recent emergence of MIS-C has posed challenges for researchers in differentiating it definitively from KD due to limited data.

Shared Immune Response in MIS-C and Kawasaki Disease

Gene Signature Analysis

Researchers from the University of California San Diego conducted a study that identified a common gene sequence, referred to as a “gene signature,” across numerous viral pandemics. An analysis of over 45,000 datasets revealed a conserved sequence present in various viral pandemics, including COVID-19 and influenza. This viral pandemic signature (ViP) comprises 166 genes that provide insight into the immune responses activated by the host, specifically humans.

Immune Activation Pathway

The ViP gene sequence triggers an immune response involving the activation of epithelial cells (skin cells) and myeloid cells (a type of immune cell) in the lungs through the IL15/IL15RA cytokine pathway. Cytokines are proteins that collaborate with the immune system to combat disease. The IL15/IL15RA pathway enhances the body’s immune response by increasing the activity of natural killer cells and specific types of T-cells, which work to manage and eliminate infections. Upon examining blood and tissue samples from patients with KD and MIS-C, researchers confirmed that both conditions activate this ViP and utilize the IL15/IL15RA pathway, indicating a shared immune response.

Severity of the Immune Response in MIS-C

Comparison of Gene Sequences

Within the ViP, a specific 20-gene sequence linked to the severity of illness, termed sViP, was identified. This sequence accurately predicted the severity of disease in both KD and MIS-C patients, as measured by the presence of coronary artery aneurysms and myocardial dysfunction. Notably, the sViP levels were found to be higher in MIS-C patients than in those with KD, indicating that the immune response in MIS-C is more severe.

Clinical Differences Between MIS-C and KD

The study also evaluated cytokine levels in patients with MIS-C and KD. Findings revealed that certain cytokines, such as TNF-alpha and IFN-gamma, were significantly elevated in MIS-C patients compared to those with KD. Although IL1-beta levels were also higher in MIS-C, this difference was not statistically significant. These results suggest that therapies targeting the TNF-alpha and IL1-beta pathways may be beneficial in treating MIS-C. Furthermore, MIS-C can be distinguished from KD by lower eosinophil levels (a type of white blood cell) and the presence of thrombocytopenia (low platelet count), both of which can be identified through simple blood tests.

Implications for Clinical Practice

Jane C. Burns, a co-author of the study and pediatrician at Rady Children’s Hospital-San Diego, emphasized the importance of timely identification and understanding of a child’s inflammatory condition to effectively tailor life-saving support. Debashis Sahoo, another co-author and associate professor of pediatrics at UC San Diego School of Medicine, highlighted the potential impact of these findings on clinical trial planning and future clinical guidelines for patient care.

References

1. Ghosh, P. et al. (2022). An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. Nature Communications; 13(2687). Doi: 10.1038/s41467-022-30357-w.
2. Riphagen, S., et al. (2020). Hyperinflammatory shock in children during COVID-19 pandemic. Lancet; 395(10237): 1607–1608. Doi: 10.1016/S0140-6736(20)31094-1.
3. Nakamura, A., Ikeda, K., and Hamaoka, K. (2019). Aetiological significance of infectious stimuli in Kawasaki disease. Frontiers in Pediatrics; 7: 1–9.
4. Rodó, X. et al. (2014). Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proceedings of the National Academy of Sciences USA; 111: 201400380.
5. Manlhiot, C. et al. (2018). Environmental epidemiology of Kawasaki disease: linking disease etiology, pathogenesis and global distribution. PLoS ONE; 13(2): e0191087. Doi: 10.1371/journal.pone.0191087.
6. Mlynaryk, N. (2022). COVID-19, MIS-C and Kawasaki disease share same immune response. EurekAlert! Accessed on May 18, 2022. Retrieved from https://www.eurekalert.org/news-releases/952614.
7. Sahoo, D. et al. (2021). AI-guided discovery of the invariant host response to viral pandemics. EBioMedicine; 68: 103390. Doi: 10.1016/j.ebiom.2021.103390.
8. Guo, Y. et al. (2017). Immunobiology of the IL-15-IL-15R[alpha] Complex as an Antitumour and Antiviral Agent. Cytokine & Growth Factor Reviews; 38: 10-21. Doi: 10.1016/j.ebiom.2021.103390.